Journal Watch · Frontiers in Immunology · 2026
Association of metabolic and inflammation vulnerabilities with systemic lupus erythematosus: a prospective UK Biobank study.
Our results suggest that MVX is valuable for risk assessment for SLE, particularly within the female population.
TL;DR
Our results suggest that MVX is valuable for risk assessment for SLE, particularly within the female population.
Key findings
- Subgroup analyses indicated that the significant association persisted across most groups, with a notable effect observed in females (HR = 1.59, 95% CI: 1.39-1.81, P < 0.01).
- RCS analysis confirmed a linear dose-response relationship, with risk thresholds of 36 for MVX, 40 for IVX, and 45 for MMX; beyond these thresholds, the risk of SLE increases as the index rises.
- Sensitivity analyses and the Fine-Gray competing risk model both confirmed the robustness of the study results, demonstrating that MVX is significantly associated with the risk of incident SLE.<h4>Conclusions</h4>MVX serves as an independent risk factor for the development of SLE.
- Notably, MVX demonstrates a stronger association with SLE risk compared to its individual components, IVX and MMX.
- Our results suggest that MVX is valuable for risk assessment for SLE, particularly within the female population.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
Sensitivity analyses included a 3-year lag exclusion, landmark analyses at 5 and 10 years, additional adjustment for C-reactive protein (CRP), the use of time-dependent covariates combined with stratification, and the use of data after multiple imputation. Additionally, the Fine-Gray competing risk model was employed treating all-cause mortality and CVD-specific mortality as competing events.<h4>Results</h4>Over a median follow-up of 13.2 years, a per standard deviation (SD) increment in MVX was associated with a 44% higher risk of SLE (HR = 1.44, 95% CI: 1.28-1.62, P < 0.01). Participants in the highest tertile (T3) of MVX had an 89% increased risk compared to those in the lowest tertile (T1) (HR = 1.89, 95% CI: 1.35-2.63, P < 0.01). Similar but attenuated associations were observed for IVX and MMX; per SD increases in IVX and MMX were associated with HRs of 1.34 (95% CI: 1.17-1.54, P < 0.01) and 1.24 (95% CI: 1.14-1.36, P < 0.01), respectively, while T3 versus T1 HRs were 1.85 (95% CI: 1.25-2.74, P < 0.01) and 1.82 (95% CI: 1.42-2.33, P < 0.01). MVX consistently demonstrated a stronger association with SLE than the sub-indices IVX and MMX.
Full abstract (original)
Background: <h4>Background</h4>Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease influenced by complex metabolic and inflammatory pathways, but the impact of specific metabolic and inflammatory signatures, particularly metabolic vulnerability index (MVX), inflammation vulnerability index (IVX), and metabolic malnutrition index (MMX), on the incidence of SLE remains unclear.<h4>Methods</h4>We evaluated the association of MVX, IVX, and MMX with the risk of incident SLE using data from 398,200 participants in the UK Biobank. MVX was constructed from IVX (calculated using glycA and small HDL particles) and MMX (calculated using citrate, isoleucine, leucine, and valine). The primary outcome was SLE based on the International Classification of Diseases, 10th Revision (ICD-10) codes. Risks were estimated using Cox proportional hazards models, while restricted cubic spline (RCS) analysis was applied to identify potential non-linear trends. Subgroup analyses were performed by demographics, comorbidities, and lifestyle factors.
What they did: Sensitivity analyses included a 3-year lag exclusion, landmark analyses at 5 and 10 years, additional adjustment for C-reactive protein (CRP), the use of time-dependent covariates combined with stratification, and the use of data after multiple imputation. Additionally, the Fine-Gray competing risk model was employed treating all-cause mortality and CVD-specific mortality as competing events.<h4>Results</h4>Over a median follow-up of 13.2 years, a per standard deviation (SD) increment in MVX was associated with a 44% higher risk of SLE (HR = 1.44, 95% CI: 1.28-1.62, P < 0.01). Participants in the highest tertile (T3) of MVX had an 89% increased risk compared to those in the lowest tertile (T1) (HR = 1.89, 95% CI: 1.35-2.63, P < 0.01). Similar but attenuated associations were observed for IVX and MMX; per SD increases in IVX and MMX were associated with HRs of 1.34 (95% CI: 1.17-1.54, P < 0.01) and 1.24 (95% CI: 1.14-1.36, P < 0.01), respectively, while T3 versus T1 HRs were 1.85 (95% CI: 1.25-2.74, P < 0.01) and 1.82 (95% CI: 1.42-2.33, P < 0.01). MVX consistently demonstrated a stronger association with SLE than the sub-indices IVX and MMX.
Results & conclusions: Subgroup analyses indicated that the significant association persisted across most groups, with a notable effect observed in females (HR = 1.59, 95% CI: 1.39-1.81, P < 0.01). RCS analysis confirmed a linear dose-response relationship, with risk thresholds of 36 for MVX, 40 for IVX, and 45 for MMX; beyond these thresholds, the risk of SLE increases as the index rises. Sensitivity analyses and the Fine-Gray competing risk model both confirmed the robustness of the study results, demonstrating that MVX is significantly associated with the risk of incident SLE.<h4>Conclusions</h4>MVX serves as an independent risk factor for the development of SLE. Notably, MVX demonstrates a stronger association with SLE risk compared to its individual components, IVX and MMX. Our results suggest that MVX is valuable for risk assessment for SLE, particularly within the female population.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1819233 · PubMed 42183279.
Why it matters for pharma & biotech
- Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
Frequently asked questions
What did this Frontiers in Immunology study find?
Our results suggest that MVX is valuable for risk assessment for SLE, particularly within the female population.
What type of study is this?
It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. Sensitivity analyses included a 3-year lag exclusion, landmark analyses at 5 and 10 years, additional adjustment for C-reactive protein (CRP), the use of time-dependent covariates combined with stratification, and the use of data after multiple imputation.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1819233. PubMed ID: 42183279. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/association-of-metabolic-and-inflammation-vulnerabilities-with-systemic-819233/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides